Abbott Laboratories reported a strong second quarter overall, but in medical devices, the company appears to be losing share in cardiac rhythm management and neuromodulation. Could Abbott's loss in these markets be Medtronic or Boston Scientific's gain?
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,